Who Owns SI-Bone Company?

Who owns SI‑BONE?

SI‑BONE went public in October 2018, raising $108,000,000, transforming it from venture-backed startup to a leading sacroiliac joint device maker. By early 2025 the iFuse system surpassed 95,000 procedures worldwide, anchoring clinical adoption and investor interest.

Majority ownership rests with institutional investors and mutual funds holding concentrated stakes, while founders and directors retain meaningful voting influence; see related analysis at SI-Bone Porter's Five Forces Analysis.

SI-BONE was co-founded in 2008 by Jeffrey Dunn and Dr. Mark Reiley, pairing executive leadership with clinical invention; early ownership blended founder equity with venture capital support to fund iFuse development and regulatory clearance.

Founders' Roles

Jeffrey Dunn served as founding CEO, bringing medical-technology executive experience; Dr. Mark Reiley provided the orthopedic and technical innovation behind iFuse.

Initial Capital

Seed and Series A funding from venture firms supplied capital for clinical trials and FDA processes, enabling early commercialization.

Key Investors

Early backers included Skyline Ventures, Norwest Venture Partners, and OrbiMed Advisors, each taking material stakes in exchange for funding.

Equity Structure

Ownership reflected a balance between founders' clinical vision and investors' commercialization focus, with typical VC vesting schedules for founders.

Governance Terms

Standard venture agreements governed control, board seats, and liquidation preferences common in 2008–2012 medical-device financings.

Clinical to Commercial

Investor involvement, notably OrbiMed and Norwest, emphasized data-driven clinical trials that supported broader adoption of iFuse.

Founders retained operational leadership through early commercialization, with no major public ownership disputes recorded and venture investors holding significant minority positions during the 2008–2012 period.

Ownership Highlights

Key facts on SI-Bone ownership and investor involvement during founding years

• Founders: Jeffrey Dunn (founding CEO) and Dr. Mark Reiley (orthopedic inventor)
• Early investors: Skyline Ventures, Norwest Venture Partners, OrbiMed Advisors
• Structure: Founder–investor equity split with VC vesting schedules and board representation
• Outcome: Clinical data-focused strategy enabled iFuse commercialization and investor-driven scale-up

For market positioning and customer segmentation context see Target Market of SI-Bone.

Complete SI-Bone Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping SI-Bone ownership include its Nasdaq IPO under ticker SIBN, gradual exit of venture and private equity backers, and growing concentration of institutional investors driving governance and performance expectations.

The ownership evolution from venture-controlled to market-controlled has tied SI-Bone’s corporate strategy to predictable revenue growth, margin expansion, and enhanced governance, supported by product-line expansion and traction in new markets; see Brief History of SI-Bone for background.

Ownership Drivers and Impact

Institutional dominance shaped priorities: quarterly consistency, margin focus, and scale initiatives.

• Institutional ownership at 94% as of early 2025
• Gross margin reached ~78% in FY2024
• 2025 revenue projected > $185 million driven by iFuse Bedrock Granite and trauma market
• Insider stake remains ~3.5%, aligning management with investors

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

SI-BONE’s board blends executive leadership and industry veterans, led by Executive Chairman Jeffrey Dunn and CEO and director Laura Francis, with independent directors and medical-device executives providing governance oversight under a one-share-one-vote structure.

The company uses a standard corporate governance model: no dual-class shares or golden shares, and voting power tied directly to equity; the top five institutional shareholders control about 45% of votes, concentrating influence over major corporate actions and executive-compensation approvals.

Board composition and voting influence

Key governance facts and implications for SI-Bone ownership and control.

• One-share-one-vote structure aligns voting with economic ownership
• Top five institutional investors hold close to 45% of voting power
• Board mix includes independent directors plus medtech executives like Keith Valentine and Erika Siliqi
• Regular board updates aim to preserve expertise in clinical affairs, global sales, and finance

Concentrated institutional ownership means large asset managers can sway outcomes on mergers, acquisitions and compensation; there have been no major proxy fights recently, and governance emphasizes transparency and periodic composition changes—see further context in this analysis: Growth Strategy of SI-Bone

SI-Bone Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Between 2022 and early 2025 SI-Bone ownership shifted toward healthcare-focused mutual funds and passive index ETFs, with secondary offerings in late 2023 and 2024 and executive equity grants reshaping the cap table.

As of early 2025 SI-Bone remains publicly traded with diversified ownership; recent filings show institutional holdings rising while insider holdings increased modestly following equity grants tied to product milestones.

Capital Raises

Late 2023 and 2024 offerings raised cash to speed iFuse-Torus commercialization and R&D; proceeds were earmarked for clinical programs and sales scale-up.

Institutional Appetite

Healthcare mutual funds increased exposure, viewing expansion into trauma and adult deformity as a multiyear growth vector.

Leadership & Ownership

CEO Laura Francis’s equity grants boosted insider stake; filings indicate insider ownership moved higher in 2024 following performance vesting tied to sales milestones.

Market Position

Analysts frequently debate SI-Bone acquisition prospects amid orthopedic consolidation, though the company reiterated independence as of early 2025; see related analysis on Revenue Streams & Business Model of SI-Bone.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE